(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the…

By Dooseop Kim, Liping Wang, M. Beconi, G. Eiermann, M. Fisher, Huaibing He, G. Hickey, Jennifer E. Kowalchick, B. Leiting, K. Lyons and 13 more. Journal of Medicinal Chemistry, 2005

782 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/373f27978799c27a53a22a720d979dfd4b3eb9e9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Wook Kim
2. Josephine M. Egan
3. C. Caria
4. D. WILLIAMS-HERMAN
5. Sitagliptin Study 023 Group
6. H. Khatami
7. L. Xu
8. M. Hanefeld

Citations in the corpus

• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “In particular, GIP phosphorylates several transcription factors such as FoxO1 and p70S6K, crucial regulators of translation known to be involved in glucose-induced -cell mitogenesis, suggesting possible mediators of GIP-mediated -cell growth (Ehses et al., 2002).”
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006, background): “Sitagliptin (MK-0431) is an orally active, potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor in development for the treatment of patients with type 2 diabetes mellitus [1].”
• Fluorine in medicinal chemistry. (2015, background): “2 Contribution of Fluorine to Pharmacokinetic Profile In vitrometabolite identification studies implicated piperazine metabolism as a problem in this second more potent series, and attempts to address this through appending heterocycles ultimately proved successful in this respect [90].”